Boston Sci stock falls 4% amid FARAPULSE study update
Boston Scientific (BSX) shares fell 5% following news that the company has paused a study for its FARAPULSE PFA system due to ...
MassDevice2d
Boston Scientific still expects Axonics deal to close this year, posts Street-beating Q3
Boston Scientific reported third-quarter results that came in ahead of the consensus forecast, raising its 2024 guidance ...
Boston Scientific lifts sales outlook, notes key approval of AFib device with Minnesota ties
The med-tech company with approximately 9,400 employees in Minnesota posted profit and sales that beat Wall Street’s ...
Boston Scientific’s stock climbs on Q3 sales and earnings beat
Boston Scientific’s BSX net income was $469 million, or 32 cents a share, down from $505 million, or 34 cents a share, in the ...
Five things: Tax compromise, community colleges, Boston Scientific, GE Vernova and the Sacred Cod
Good morning, Boston. Here are the five things you need to know in local business news to start your busy Thursday.
Boston Scientific Pauses Enrollment In Farapulse Study In Drug-Naive Patients With Irregular Heart Rhythm
Boston Scientific's AVANT GUARD trial evaluates the FARAPULSE PFA System for treating persistent atrial fibrillation, pausing ...
Boston Scientific Q3 Earnings Preview
In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the ...
Boston Scientific’s Robust Performance and Growth Prospects Drive Buy Rating
William Plovanic, an analyst from Canaccord Genuity, maintained the Buy rating on Boston Scientific (BSX – Research Report). The ...
Boston Scientific Corporation (BSX) Q3 2024 Earnings Call Transcript
Good morning and welcome to the Boston Scientific Third Quarter 2024 Earnings Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an ...